Celgene was created in 1986.
The population of Celgene is 4,182.
The ticker symbol for Celgene is CELG and it is traded on the Nasdaq.
The symbol for Celgene Corporation in NASDAQ is: CELG.
Celgene Corporation (CELG) had its IPO in 1987.
As of July 2014, the market cap for Celgene Corporation (CELG) is $138,047,705,276.52.
celgene
The CUSIP for Celgene Corporation is 151020104. CUSIP numbers are unique identifiers assigned to financial instruments in the United States, including stocks and bonds, to facilitate the clearing and settlement process. Celgene was acquired by Bristol-Myers Squibb in 2019, so the CUSIP may no longer be actively used for trading.
Pharmion was sold to Celgene Corporation, which is ticker symbol "CELG"
Celgne produces innovative and life-changing pharmaceutical drugs. They focus on the discovery, development, and commercialization of products for cancer, and other severe, immune, and inflammatory conditions.
According the the website 'TheStreet' the highest Biotech stock is Amgen Inc with a A+. Some of the other top Biotech stocks include Celgene Corp, Biogen IDEC INC, and United Therapeutics Corp.
According to Med Ad News, a magazine focused on the pharmaceutical business, the bio-tech companies focusing on newer technologies include Roche, Amgen, Gilead Sciences, Biogen Idec, and Celgene.
Azacitidine injection is manufactured by several pharmaceutical companies, including Celgene Corporation, which is now part of Bristol-Myers Squibb. The drug is marketed under the brand name Vidaza. It is used primarily for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Always check with a healthcare provider or the latest resources for the most current information on drug manufacturers.